Another 14 generics threaten Eli Lilly's blockbuster chemotherapy Alimta
Eli Lilly was able to fend off generic competition to its chemotherapy drug Alimta for quite some time, defending its patents in a series of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
